Ophthalmic treatment solution delivery devices and delivery augmentation methods

Information

  • Patent Grant
  • 11931291
  • Patent Number
    11,931,291
  • Date Filed
    Thursday, January 9, 2020
    4 years ago
  • Date Issued
    Tuesday, March 19, 2024
    8 months ago
  • Inventors
  • Original Assignees
    • EPION THERAPEUTICS, INC. (Burlington, MA, US)
  • Examiners
    • Lee; Brandy S
    • Crawford; John J
    Agents
    • PROCOPIO, CORY, HARGREAVES & SAVITCH LLP
Abstract
A first sponge device for use to manipulate and prepare the surface of the epithelium of an eye prior to application of an ophthalmic solution has a handle and a sponge head secured to the handle. The head is made of an absorbent, wicking sponge material and has a non-sharp, tissue preparation surface of predetermined shape for rubbing across the surface of the epithelium layer in order to manipulate the tissue. After the surface is prepared, a second, holding sponge is placed over the eye to act as a reservoir and to hold ophthalmic solution against the eye surface.
Description
BACKGROUND

Collagen cross-linking is a treatment for multiple ophthalmic disorders. In some cases, collagen cross-linking may also be combined with other treatments to improve corneal strength or optical refraction, such as corneal ring segment inserts, topography-guided laser, and the like. Corrective lenses are normally required after these treatments for weakened corneas, but with smaller, more normalized prescriptions. Increased corneal symmetry allows for more comfortable contact lens wear, often of daily disposable lenses. Collagen cross-linking limits deterioration of vision, increases unaided and uncorrected vision, and may reduce the need for corneal transplantation. Collagen cross-linking may also have a role in stabilizing and “locking in” refractive effects of other procedures.


SUMMARY

Disclosed herein, in certain embodiments, is a method of applying an ophthalmic composition to an eye, comprising applying the ophthalmic composition after preparing the epithelium of an eye for more effective treatment. In some embodiments, the method comprises preparing the epithelium of the eye by rubbing or contacting the eye with a first sponge device, so as to manipulate or “buff” the tissue of the epithelium. In some embodiments, the method comprises preparing the epithelium of the eye by rubbing the eye with the first sponge device in a circular pattern. In some embodiments, the method comprises removing lipids, mucus and microvilli. In some embodiments, the first sponge device comprises a handle with a sponge attached to one end of the handle for contacting the eye. In some embodiments, the sponge is dry or pre-wetted with an ophthalmic composition. In some embodiments, the sponge is pre-wetted with a riboflavin composition, artificial tears, or a combination thereof. In some embodiments, use of the first sponge device to prepare the epithelium markedly increases the permeability of the epithelium to medications or ophthalmic solutions applied to the surface of the epithelium after preparation or polishing with the buffing or polishing sponge.


In some embodiments, the method further comprises applying the ophthalmic composition with a second, loading sponge or sponge device. In some embodiments, the method further comprises placing the second sponge or sponge device over the eye to act as a depot or reservoir for holding the ophthalmic composition or solution in contact with the eye surface over an area where the solution needs to be absorbed into the eye.


In certain embodiments, the second sponge device comprises a round, loading sponge which peri- or pre-operatively covers all or a portion of the eye surface. In some embodiments, the size of the loading sponge does not exceed the eye surface. In some embodiments, the diameter of the sponge is about 3 mm. to about 12 mm. In some embodiments, the second sponge device has a diameter of around 11.5 mm and may be pre-formed to follow the curvature of most or all of the exposed, curved surface of the eye or may be of flexible material designed to adopt the shape of the exposed, curved surface of the eye. In some embodiments, the second sponge device or loading sponge may be pre-saturated with an ophthalmic solution. In some embodiments, the second sponge device may be placed on the eye surface and solution can be dripped onto the sponge device after placement. In some embodiments, the ophthalmic solution may comprise 0.2% to 10.0% by weight riboflavin in an aqueous carrier, and optionally, sodium iodide, catalase, artificial tears, or any combinations thereof.


Disclosed herein, in certain embodiments, is a first or preparation sponge device for use in manipulation of tissue on the surface of an eye prior to application of the second sponge device or loading sponge. The first, preparation sponge device comprises a preparation sponge having a tissue preparation surface shaped for manipulating and rubbing across the surface of an eye. In some embodiments, the preparation sponge has little or no risk of disrupting or perforating the epithelium. In some embodiments, the first sponge device further comprises a handle operatively connected to the preparation sponge. In some embodiments, the first sponge device may be a spherical or part spherical sponge without a handle, and may be held by forceps or similar instruments during preparation of the eye surface. In some embodiments, at least the tissue preparation surface of the sponge is round or at least partially round. In some embodiments, at least the tissue preparation surface of the sponge does not have sharp edges. In some embodiments, the tissue preparation surface of the sponge is rounded. In some embodiments the sponge of the first sponge device is of part circular shape. In some embodiments, the sponge may have a straight edge or other shaped edge attached to the handle. In some embodiments, the preparation sponge is made of a cellulose sponge material. In some embodiments, the preparation sponge is made of polyvinyl acetate (PVA) sponge material. In some embodiments, the preparation sponge is wetted with an ophthalmic solution prior to use in preparation of the eye surface. In some embodiments, the ophthalmic solution is 0.2% to 10.0% by weight riboflavin in an aqueous carrier, and optionally, sodium iodide, catalase, artificial tears, or any combinations thereof.


Use of the first, preparation sponge device followed by the second sponge device or loading sponge may augment or enhance delivery of any ophthalmic treatment solution to the eye for use in photochemical treatment of the cornea or for other types of treatment, such as application of eye medications such as glaucoma medications or anti-inflammatory medications such as steroids. In certain embodiments, the treatment solution is a riboflavin solution.


Disclosed herein, in certain embodiments, are sponges that improve the passage or penetration of riboflavin or other ophthalmic drugs through the epithelial barrier to avoid the surgical complications that arise from de-epithelialization, which can result in more disruption of the tissue than is necessary for the procedure to be effective. The reduction in patient discomfort combined with more rapid restoration of visual acuity make a trans-epithelial procedure better for the patient. In some embodiments, the first and second sponge devices are sterile. In some embodiments, the preparation sponge is part circular shape when dry and is configured to absorb liquid and expand into a spherical or part-spherical shape when wetted. In some embodiments, the preparation sponge is spherical or part-spherical in its dry condition. The preparation sponge may be of cellulose, PVA, or urethane sponge material. The first sponge device or preparation sponge has little or no risk of disrupting or perforating the epithelium, resulting in as little disruption of the epithelium as possible while still increasing penetration of the riboflavin or other solution into the deeper layers of the cornea without disrupting or causing any significant epithelial defects in the corneal surface.


In some embodiments, the first or preparation sponge device is of sponge or other sponge-like materials designed to enhance epithelial permeability by gently removing lipids, mucus, and dead surface epithelial cells. In some embodiments, the preparation sponge is packaged along with a blunt plastic shaft or other tool to assist in “twirling” this sponge around on the cornea or sclera or other parts of the eye to manipulate the tissue to be treated in an effort to enhance penetration of the riboflavin or other solution into the eye.


Further disclosed herein, in certain embodiments, is a method of using a first sponge device or preparation sponge as disclosed herein to improve the penetration of riboflavin or other ophthalmic drugs through the epithelial barrier to avoid the surgical complications that arise from de-epithelialization, which in some embodiments result in more disruption of the tissue than is necessary for the procedure to be effective. The reduction in patient discomfort combined with more rapid restoration of visual acuity make a trans-epithelial procedure better for the patient. In some embodiments, the preparation sponge is rubbed gently over the surface of the eye in a circular pattern after application of a topical anesthetic, in order to prepare the epithelium for improved penetration of riboflavin or other solutions. In some embodiments, the method removes lipids, mucus, microvilli and other natural barriers to riboflavin or other ocular solutions loading into the deeper ocular tissues. In some embodiments, it is possible that this preparation may produce very fine micro-abrasion to allow the riboflavin solution to penetrate through the epithelium into the cornea more easily, but this is not essential and may not occur in all cases. In some embodiments, the method has little or no risk of disrupting or perforating the epithelium resulting in as little disruption of the epithelium as possible while still increasing penetration of the riboflavin or other solution into the deeper layers of the cornea. In some embodiments, the method further comprises applying an ophthalmic solution (e.g., a riboflavin solution) to the eye in any suitable manner. In some embodiments, the ophthalmic solution is applied through a second, loading sponge placed over the eye to act as a depot or reservoir for the ophthalmic solution, since the tear film itself is only about 5 microns thick, which offers only a very small reservoir of riboflavin solution. This also moisturizes the corneal surface.


In various embodiments, the sponge device is used in one or more microsurgical ophthalmic procedures for tissue manipulation and management of fluids. In other embodiments, the sponge device is used in one or more microsurgical ophthalmic procedures for the management of one or more fluids. In some embodiments, the sponge device is placed on the cornea to moisten the cornea during one or more microsurgical procedures.


The above devices and methods may be used in various microsurgical ophthalmic procedures, including preparation of the epithelium for loading of one or more fluids through the epithelium into the eye for photochemical or other treatment.


Other features and advantages of the present disclosure will become more readily apparent to those of ordinary skill in the art after reviewing the following detailed description and accompanying drawings.





BRIEF DESCRIPTION OF THE DRAWINGS

The details of the present disclosure, both as to its structure and operation, may be gleaned in part by study of the accompanying drawings, in which like reference numerals refer to like parts, and in which:



FIG. 1 exemplifies an enlarged perspective view of one embodiment of a preparation or tissue manipulating sponge device for use in preparing the corneal epithelium for subsequent application of an ocular treatment solution to the eye;



FIG. 2 is a cross section on the lines 2-2 of FIG. 1;



FIG. 3A is a top plan view of a spear shaped sponge attached to the handle of FIGS. 1 and 2 prior to cutting the sponge into the rounded shape of FIGS. 1 and 2, according to one example of a method of making the preparation sponge device of FIGS. 1 and 2;



FIG. 3B is a top plan view of a sponge blank attached to the handle of FIGS. 1 and 2 prior to cutting the sponge into the rounded shape of FIGS. 1 and 2, according to another example of a method of making the preparation sponge device of FIGS. 1 and 2



FIG. 4 is a cut away top perspective view of the tissue preparation sponge device of FIGS. 1 to 3, showing the sponge head with part of the handle cut away, with the sponge head in a dry condition;



FIG. 5 is a side elevation view of the preparation sponge device of FIGS. 1 to 4, with the handle partially cut away as in FIGS. 2 and 4;



FIG. 6 is a top end perspective view of the preparation sponge device of FIGS. 1 to 5, with the handle partially cut away as in FIGS. 4 and 5;



FIGS. 7 to 9 are cut away views of the preparation sponge device corresponding to the views of FIGS. 4 to 6 but with the sponge head in a wet, expanded condition;



FIG. 10 illustrates an exemplary use of the sponge of FIGS. 1 to 9 to manipulate the corneal surface in a swirl action;



FIGS. 11A to 11C are top plan views illustrating some other embodiments of the buffing or polishing sponge device with a sponge head of circular shape;



FIG. 12 is a top plan view illustrating another embodiment of the buffing or polishing sponge device having a spherical sponge head;



FIG. 13 is a perspective view illustrating an embodiment of a second sponge device or loading sponge placed on an eye for holding and loading of an ophthalmic treatment solution;



FIG. 14 is a vertical cross-sectional view illustrating the second sponge device of FIG. 13 following the curvature of most of the eye surface, with details of the eye itself omitted;



FIG. 15 is a perspective view similar to FIG. 13 illustrating a modified embodiment of a round loading sponge; and



FIG. 16 illustrates tabulated examples of corneal saturation or loading times (in minutes) for a 0.1% riboflavin solution and a 0.5% riboflavin solution when the epithelium is prepared or manipulated with the sponge device of FIGS. 1 to 9 and one of the solution holding or loading sponges of FIGS. 13 to 15 is used to load the riboflavin treatment solution.





DETAILED DESCRIPTION

Certain embodiments as disclosed herein provide for ocular treatment solution delivery devices and delivery augmentation methods. For example, according to embodiments of the disclosure, devices and methods are provided for preparing the corneal epithelium for better penetration of riboflavin solutions or other ophthalmic solutions into the cornea.


A popular treatment of corneal diseases, including keratoconus, post-LASIK ectasia, and pellucid marginal degeneration, involves the removal of the epithelium followed by administration of a riboflavin solution and irradiation by ultraviolet-A light. Riboflavin acts as a photosensitizer and facilitates the cross-linking of stromal collagen fiber which prevents further disease progression. However, the removal of the epithelium carries numerous risks for the patient, including post-operative pain, infection risk, delayed wound healing, corneal perforation, stromal haze, and herpetic keratitis. Therefore, it would be safer to treat the patient without having to surgically remove the epithelium. Unfortunately, there are many obstacles to this approach because the intact epithelium prevents the cornea from rapidly and conveniently absorbing the riboflavin solution. This invention discloses novel devices and methods for allowing convenient treatment of corneal diseases with medications or with ophthalmic solutions such as riboflavin solutions without removing the epithelium, and may increase the effectiveness of such treatments.


After reading this description it will become apparent to one skilled in the art how to implement the disclosure in various alternative embodiments and alternative applications. However, although various embodiments of the present disclosure will be described herein, it is understood that these embodiments are presented by way of example only, and not limiting. As such, this detailed description of various alternative embodiments should not be construed to limit the scope or breadth of the present disclosure as set forth in the appended claims.


The time period for sufficient riboflavin to penetrate into the cornea when the solution is applied in drops to the eye without removal or treatment of the epithelium layer can be one to three hours. This is a problem for both patients undergoing treatment and for surgeons, in view of the extended time period needed. In some embodiments described below, eye surface preparation or manipulation reduces the initial time needed for an ophthalmic solution (e.g., a riboflavin solution or other ophthalmic solution) to penetrate sufficiently into the cornea in as little as seven to eleven minutes without requiring removal of the epithelium, significantly reducing patient discomfort and the time needed to complete the treatment.


Manipulation of the epithelium prepares it for improved penetration of the epithelium by the ophthalmic solution (e.g., a riboflavin solution), without having to remove the epithelium altogether. The cornea absorbs the riboflavin well until the corneal stroma is sufficiently loaded.



FIGS. 1 to 10 illustrate an exemplary device and method for improving the penetration of riboflavin or other ophthalmic solutions or fluids through the epithelial barrier, while avoiding the surgical complications that arise from deepithelialization. The reduction in patient discomfort, the more rapid restoration of visual acuity, and the reduced risk of infection or stromal haze make a trans epithelial procedure better for the patient.


In some embodiments, a first or preparation sponge device 20 as illustrated in FIG. 1-9 is rubbed gently over the surface of the eye 26 after application of a topical anesthetic, as illustrated in FIG. 10. The sponge may be rubbed gently in a circular or swirling manner, in order to manipulate the eye surface, in other words to “buff” or “polish” the eye to a dull sheen. In one embodiment, preparation sponge device 20 comprises an elongate handle or shaft 21 with a gripping portion 22 at one end and a sponge head 24 of relatively rigid sponge material attached to the other end of shaft 21, as illustrated in FIG. 1. When dry, the head 24 of this embodiment is a generally flat, part-circular or part disk shaped piece of surgical or medical grade sponge material such as relatively rigid, highly absorbent natural cellulose or highly absorbent, fast wicking polyvinyl acetate (PVA) material or the like, for example Ultracell® PVA or other sponge materials used in Weck-Cel® fluid control medical sponges as manufactured by Beaver-Visitec of Waltham, Mass. The handle shaft 21 may be of any suitable material, such as injection molded plastic material, and may be transparent or opaque.


Sponge 24 has a rounded edge or rim 25 and a straight edge or rim 27, and is held at the center of the straight edge in recess 28 between spaced claws or end portions 29 of the shaft 21, as illustrated in FIG. 2. Sponge 24 may be secured in recess 28 via adhesive or the like. FIGS. 3A and 3B illustrate some alternative methods for manufacture of the preparation sponge device 20. The manufacturing method may be similar to that for conventional spear shaped medical sponges. In FIG. 3A, a spear shaped sponge 35 is secured to handle 21, and sponge 35 is then cut along line 25 to form part circular sponge 24. The thus-formed rounded edge or rim 25 forms more than half of the periphery of a circle, as can be seen in FIG. 3A. In FIG. 3B, a sponge blank 36 is attached to handle 21, and is cut along line 25 to form the part-circular sponge 24. In each case, the rounded edge 25 passes the half way or semi-circle point and starts to curve back in towards the handle, as illustrated in FIGS. 1 and 4. The thickness of the sponge may be around 1 mm while the diameter of the part circular sponge may be in the range from 4.5 mm to around 8 mm. In one example, the diameter of the part-circular edge was about 6.5 mm.



FIGS. 1, 2 and 4 to 6 illustrate the sponge device 20 from different directions, with the sponge 24 in a dry, unexpanded state. When the sponge is wetted, the sponge material swells and continues to swell until it creates a rounded ball-like or substantially spherical shape, as illustrated in FIGS. 7 to 9. The handle attachment at the center of the sponge restricts the central portion from swelling, while allowing the remainder of the sponge to swell or expand freely, creating eye preparation surfaces 30 which are all rounded when the sponge is sufficiently wetted, as seen in FIGS. 7 to 9. Because the sponge comprises more than half of a circle and the straight edge 27 of the sponge faces towards the handle when the device is in use, the straight edges on each side of the attachment area are moved away from the treatment area as the sponge device is wetted and expands, forming a generally V-shape as seen in FIGS. 7 and 9. This moves edge surfaces away from the treatment area and avoids the risk of an edge surface contacting the eye.


In some embodiments, the sponge 24 is pre-wetted prior to use so that it is in the expanded condition of FIGS. 7 to 9 before contacting the eye. Once wetted, the material has a softness and roundness that reduces the risk of causing epithelial defects when rubbing gently over the epithelial surface of the eye, as illustrated in FIG. 10. In other embodiments, the sponge may not be pre-wetted prior to use, but starts swelling and rounding up when touched to the tear meniscus from contact with eye fluids, so that it softens prior to the eye surface preparation procedure.


In some embodiments, rubbing or buffing the epithelium gently with the expanded sponge 24 removes lipids, mucus and microvilli as well as dead epithelial cells which would otherwise resist penetration of fluid through the epithelium. In some embodiments, the wet sponge is rubbed gently over the surface of the eye, for example in a circular pattern. In some embodiments, a topical anesthetic is applied to the eye before the application and use of the wet sponge.



FIGS. 11A to 11C illustrate modified sponge devices 75A, 75B and 75C, respectively, which are similar to the sponge device of FIGS. 1 to 9, but have a completely circular head 76A, 76B, 76C attached to handle 21 instead of a part circular head with a straight lower edge as in the first embodiment. In some embodiments, the head diameters in FIGS. 11A to 11C are around 8 mm, 6.5 mm, and 4.5 mm, respectively, and the dry sponge head has flat opposite faces as in the first embodiments. When wetted, the sponge heads of FIGS. 11A to 11C also expand to a substantially spherical shape. Modified sponge device 78 of FIG. 12 has a spherical head 80 of expanded foam material. This device is ready to use with a completely rounded surface, and absorbs liquid at a faster rate than the dry, compressed foam heads of the previous embodiments. Head 80 may be made of urethane sponge material, for example. This sponge device maintains structural rigidity for preparation of the epithelium for penetration of riboflavin solutions or other solutions or medications.


Any suitable sponge shape or material is contemplated for use with the methods disclosed herein, including the sponge head shape of the first embodiment (FIGS. 1 to 10) as well as the alternative sponge head shapes of FIG. 11A to 12, as well as other shapes. In alternative embodiments, the preparation sponge device may be of more oval, Q-tip like shape, or may comprise a sponge or instrument wipe wrapped around a finger. However, the sponge head shape of FIGS. 1 to 10 is found to work well in reducing the risk of causing injury or epi-defects while improving delivery of ophthalmic solution to the cornea, due to the generally rounded shape as well as the elimination of any sharp edges in the eye preparation surface portion when the sponge is wetted and expands as seen in FIGS. 7 to 9. The sponge heads of FIG. 11A to 11C will also expand to a rounded, partially or completely spherical shape on wetting. The spherical sponge head of FIG. 12 is already completely expanded and rounded prior to use and absorbs liquid at a faster wicking rate than the heads of the other embodiments which are of dry compressed foam. The sponge heads in any of the preceding embodiments may be pre-wetted either prior to application to the eye or by placing on the eye surface to absorb tears, after which the head tends to swell or expand to a more rounded off shape with no sharp edges in the partially spherical tissue preparation surface.


After completion of the polishing or buffing step, an ophthalmic solution is applied to the eye in any suitable manner. In some embodiments, the ophthalmic solution is applied through a second sponge device which comprises a solution holding or loading/moistening sponge 24 placed over the eye 26 as illustrated in FIGS. 13 and 14. Sponge 40 of FIG. 13 is circular and is thin enough to form to the curvature of the eye surface 41, as illustrated in FIG. 14. In some embodiments, solution holding or loading sponge 40 is of diameter large enough to cover or drape over all or most of the eye when centrally positioned as illustrated in FIGS. 13 and 14, while in other embodiments, a smaller diameter loading sponge 80 which covers the corneal area of the eye only may be used, as illustrated in FIG. 15, depending on the desired treatment area. In the embodiment of FIGS. 13 and 14, the sponge diameter is in the range from about 10 mm to about 12 mm, and has a thickness of the order of about 0.5 mm to about 3 mm. In one embodiment, the sponge diameter is about 11.5 mm. FIG. 15 illustrates smaller diameter solution holding or loading sponge 80 which covers at least the corneal area of the eye and may have a diameter in the range from about 3 mm to about 9 mm. In some embodiments, the sponges 40 and 80 are in the range of about 0.5 mm to about 5 mm in thickness. In some embodiments, the sponge becomes more flexible when soaked in ophthalmic solution so that it adopts the curvature of the eye when placed and thus contacts most of the area of the eye to allow the solution to penetrate through the epithelium into the cornea or other underlying regions of the eye. Sponge 40 may also be pre-formed in a dry state to conform or fit to the curvature of the eye surface. Although FIGS. 13 and 15 illustrate the eye being held open by a speculum during the solution loading procedure, this is often not necessary either for the eye preparation step of FIG. 12 or the loading procedure using sponge 40 or 80. In fact, the surgeon may hold the eye open manually during these procedures, or in some cases the patient may simply try not to blink.


In some embodiments, the ophthalmic solution is dripped onto the holding or loading sponge while it is placed over the eye, or the sponge is pre-soaked with the ophthalmic solution, or both. The second, loading sponge, for example sponge 40 or 80, acts as a reservoir to hold the solution against the eye surface and to allow application of additional solution. Simply dropping ophthalmic solution directly onto the eye surface or placing drops onto the eye results in the drops running off the eye, and has a limited effect. In contrast, the solution holding sponge of this embodiment places ophthalmic solution directly against the surface of the eye in a location where treatment is needed over an extended time period, allowing more efficient penetration into the cornea. In some embodiments, the ophthalmic solution is a riboflavin solution of 0.2% to 10.0% by weight riboflavin in an aqueous carrier, and optionally, sodium iodide, catalase, artificial tear solution or any combination thereof. If the sponge is pre-loaded with riboflavin, it is stored in a dark packaging material prior to use to avoid or reduce light degradation. In some embodiments, the riboflavin solution contains other additives for increased cross-linking, for example additives as described in PCT Application Publication No. WO 2013/148896. In some embodiments, the sponge is round, but the sponge may be of other shapes (such as oval or eye shaped) in alternative embodiments. In some embodiments, the solution holding or loading sponge operatively covers all or a portion of the eye or the cornea. In some embodiments, the holding sponge is made from any suitable sponge material such as cellulose or any fast wicking, lint-free material such as polyvinyl acetate, for example any of the materials described above in connection with the manipulation or preparation sponge devices of FIGS. 1 to 12. The sponge material of both the preparation sponge device 20 and the holding or loading sponge 40 in one embodiment was PVA sponge material with a pore size in the range of about 60 microns to about 1000 microns. In one embodiment, the pore size of both sponges was in the range from about 60 to about 120 microns. In one example, the pore size was about 60 microns. In one embodiment, the holding or loading sponge may have a larger pore size than the preparation sponge 24 in order to hold more liquid for corneal loading purposes.


Where the sponge is a round sponge, the sponge operatively covers all or a portion of the eye or the cornea. In some embodiments, the size of the sponge does not exceed the size of the eye or the cornea. In some embodiments, the diameter of the sponge is about 3 mm to about 12 mm. In some embodiments, the sponge is about 1 mm to about 5 mm in thickness. A series of different diameter loading sponges may be provided for selection by the physician depending on the desired treatment area.


The above sponges may be used in the two stage method described above for enhanced, faster penetration of any ocular treatment solution through the epithelium and into the cornea, while reducing or minimizing the risk of epithelial defects. The ophthalmic solution may be an ocular riboflavin solution for use in corneal treatment such as photochemical cross linking, or for other ophthalmic uses. In one embodiment, the method may be used for application of a riboflavin solution which contains 0.1 wt. % to 5.0 wt. % riboflavin in an aqueous carrier solution, or up to 10.0% in some cases. In some embodiments, the solution contains about 0.5 wt. % riboflavin. In other examples, the solution contains about 1.0 wt. % riboflavin or about 2.0 wt. % riboflavin. The higher concentration of riboflavin can increase corneal cross-linking if associated with higher amounts of oxygen in the cornea. The riboflavin solution may be stored in an actinic glass or UV and visible light protected plastic containers prior to use, to avoid activation of the riboflavin by ambient light.


The above devices and methods are designed to increase permeability of the epithelium layer with low or minimal epithelial defects resulting from the preparation or tissue manipulation step. Results of testing show that use of the sponge of FIGS. 1 to 9 with a part-circular edge, which expands to a part-spherical or ball-like shape when wetted, may eliminate or substantially eliminate epithelial defects. Similar results may be achieved with the sponges of FIGS. 11A to 11C with a completely circular edges, which also expand to a completely or partially spherical shape, as well as the sponge device of FIG. 12, which is pre-expanded to a spherical shape. Methods using the preparation sponge device of FIGS. 1 to 9 and the loading or holding sponge device of FIGS. 13 to 15 have also been found to significantly reduce the time needed for sufficient riboflavin solution to penetrate into and saturate the cornea, as compared to the time needed with no pre-treatment of the epithelium to increase permeability. Some examples are provided below.


EXAMPLE

Two formulations of riboflavin solution were tested to determine saturation or riboflavin solution loading time after pre-treatment of the epithelium using the preparation sponge devices of the above embodiments. Formulation 1 had a riboflavin concentration of 0.1%. Formulation 2 had a riboflavin concentration of 0.5%. Results are compared in FIG. 16.


Saturation was determined using “serial slit-lamp assessments” of the cornea at approximately 5 minute intervals. Riboflavin has a characteristic green color when illuminated with visible light. Slit-lamp assessments using visible light reveal the depth and uniformity of riboflavin throughout the corneal thickness.


Inclusion Criteria:


Patients who had undergone trans-epithelial cross-linking in one or both eyes were included in the analysis. Patients with a diagnosis of keratoconus or post-LASIK ectasia were included in this analysis.


Exclusion Criteria:


Patients with previous RK, INTACS, more than one cross-linking procedure per eye, and/or patients who were pseudo-phakic or had a diagnosis of nuclear sclerotic cataract were excluded from this analysis


Results—Formulation 1, 0.1% Riboflavin, Formulation 2, 0.5% Riboflavin


The results are shown in FIG. 16. Trans epithelial loading time using one of the loading sponges described above with formulation 1 ranged from 30 minutes minimum to 56 minutes maximum, with an average loading time of 40.4 minutes. Trans epithelial loading time with formulation 2 ranged from 7 to 30 minutes with an average loading time of 12.14 minutes.


The time period for good, homogeneous loading of riboflavin solution into the cornea, i.e. trans epithelial riboflavin loading time, was about 10 to 30 minutes using the delivery augmentation and delivery methods described above. Corresponding loading times without removal or pre-treatment of the epithelium can be up to three hours, significantly adding to the overall time for completion of a corneal treatment procedure.


The above description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles described herein can be applied to other embodiments without departing from the spirit or scope of the invention. Thus, it is to be understood that the description and drawings presented herein present exemplary embodiments of the invention and are therefore representative of the subject matter which is broadly contemplated by the present invention. It is further understood that the scope of the present invention fully encompasses other embodiments that may become obvious to those skilled in the art and that the scope of the present invention is accordingly limited by nothing other than the appended claims.

Claims
  • 1. A delivery system for delivery of ophthalmic solutions to an eye, comprising: an eye surface preparation sponge device comprising a handle and a head secured to the handle, wherein the head is formed entirely from a single absorbent, fast-wicking sponge material, wherein the head is configured to expand from a first configuration having a circular disk shape or part circular disk shape with opposite flat surfaces when dry to a second configuration different from the first configuration and having a spherical or part spherical shape when wetted, at least the second configuration having no sharp edges, and wherein the head includes an epithelial tissue preparation surface configured for rubbing across a curved surface of the epithelium of the eye to prepare the curved surface for penetration by an ophthalmic solution; anda loading sponge for use in holding the ophthalmic solution against the curved surface of the eye, wherein the loading sponge comprises a size large enough to cover an entire cornea of the eye and a thickness of between 0.5 mm and 5 mm, wherein the loading sponge acts as a reservoir to hold the ophthalmic solution against the curved surface of the eye where treatment is needed over an extended time period, allowing efficient penetration of the ophthalmic solution into the cornea.
  • 2. The delivery system of claim 1, wherein the size is a diameter is between 10 mm and 12 mm.
  • 3. The delivery system of claim 1, wherein the size is a diameter is between 3 mm and 9 mm.
  • 4. The delivery system of claim 1, wherein the thickness is between 0.5 mm and 3 mm.
  • 5. The delivery system of claim 1, wherein application of the ophthalmic solution onto the loading sponge causes the loading sponge to be more flexible such that it adapts to a curvature of the curved surface of the eye.
  • 6. The delivery system of claim 1, wherein the loading sponge is pre-formed in a dry state to conform to a curvature of the curved surface of the eye.
  • 7. The delivery system of claim 1, wherein the loading sponge is wetted with the ophthalmic solution, and wherein the ophthalmic solution comprises 0.2% to 10% by weight riboflavin in an aqueous carrier.
  • 8. The delivery system of claim 7, wherein the ophthalmic solution further comprises at least one of sodium iodide, catalase, and an artificial tear solution.
  • 9. The delivery system of claim 1, wherein the loading sponge is made of a fast-wicking, lint-free material; or made of cellulose.
  • 10. The delivery system of claim 9, wherein the fast-wicking, lint-free material comprises polyvinyl acetate.
  • 11. The delivery system of claim 1, wherein the loading sponge is made of a material having a pore size in the range of between 60 and 120 microns.
  • 12. The delivery system of claim 1, wherein the loading sponge is a circular, disc-shaped sponge.
  • 13. The delivery system of claim 1, wherein a thickness of the head of the eye surface preparation sponge device in a dry condition is in the range from 0.5 mm to 3 mm.
  • 14. The delivery system of claim 1, wherein a diameter of the head of the eye surface preparation sponge device is in the range from 4.5 mm to 8 mm.
  • 15. The delivery system of claim 1, wherein the single absorbent, fast-wicking sponge material comprises polyvinyl acetate.
  • 16. The delivery system of claim 15, wherein a pore size of the single absorbent, fast-wicking sponge material is in the range from 60 to 120 microns.
  • 17. The delivery system of claim 1, wherein at least one of the head of the eye surface preparation sponge device and the loading sponge is pre-wetted with the ophthalmic solution.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation application of U.S. application Ser. No. 14/275,192, filed May 12, 2014, which is a continuation-in-part of International Application PCT/US2013/034187, filed Mar. 27, 2013, which claims priority to U.S. Provisional Application No. 61/617,339, filed Mar. 29, 2012, all of which are incorporated by reference herein in their entireties.

US Referenced Citations (330)
Number Name Date Kind
3132068 Behrman May 1964 A
4098728 Rosenblatt Jul 1978 A
4676790 Kern Jun 1987 A
4863627 Davies et al. Sep 1989 A
5368590 Itoh Nov 1994 A
5433714 Bloomberg Jul 1995 A
5639481 Kessler et al. Jun 1997 A
5824073 Peyman Oct 1998 A
5843060 Cercone Dec 1998 A
5849291 Kessler Dec 1998 A
5954682 Petrus Sep 1999 A
6043237 Meadows et al. Mar 2000 A
6053936 Koyama et al. Apr 2000 A
6099521 Shadduck Aug 2000 A
6161544 Devore et al. Dec 2000 A
6162210 Shadduck Dec 2000 A
6183086 Neubert Feb 2001 B1
6192888 Chandler et al. Feb 2001 B1
D439655 Chandler Mar 2001 S
6248335 Duan et al. Jun 2001 B1
6309656 Pugliese et al. Oct 2001 B1
6413268 Hartman Jul 2002 B1
6447537 Hartman Sep 2002 B1
D464429 Martin et al. Oct 2002 S
6471691 Kobayashi et al. Oct 2002 B1
6544165 McNew Apr 2003 B1
6544286 Perez Apr 2003 B1
6783539 Timberlake et al. Aug 2004 B1
6880558 Perez Apr 2005 B2
6905641 Platt et al. Jun 2005 B2
7015252 Fujii et al. Mar 2006 B2
7044945 Sand May 2006 B2
7073510 Redmond et al. Jul 2006 B2
7077839 Hamblin et al. Jul 2006 B2
7097629 Blair Aug 2006 B2
7186417 Siegel et al. Mar 2007 B1
7220278 Peyman May 2007 B2
7288106 Heacock et al. Oct 2007 B2
7320786 Chen Jan 2008 B2
7331350 Kochevar et al. Feb 2008 B2
7479136 Dotson Jan 2009 B2
7498156 Goodrich et al. Mar 2009 B2
7727544 Schwartz et al. Jun 2010 B2
7744590 Eells et al. Jun 2010 B2
7753943 Strong Jul 2010 B2
7892268 Heacock et al. Feb 2011 B2
7943590 Flugelman May 2011 B2
8034373 Reynolds et al. Oct 2011 B2
8071135 Liu et al. Dec 2011 B2
8092490 Redmond et al. Jan 2012 B2
8100530 Zhou et al. Jan 2012 B2
8106038 Margaron et al. Jan 2012 B2
8177778 Muller et al. May 2012 B2
8202272 Muller et al. Jun 2012 B2
8215314 Chan et al. Jul 2012 B2
8238993 Maynard et al. Aug 2012 B2
8282629 Mrochen et al. Oct 2012 B2
8348935 Muller et al. Jan 2013 B2
8366689 Marshall et al. Feb 2013 B2
8398628 Muller Mar 2013 B2
8409189 Muller Apr 2013 B2
8414911 Mattson et al. Apr 2013 B2
8460278 Muller Jun 2013 B2
8466203 Paik et al. Jun 2013 B2
8469952 Muller et al. Jun 2013 B2
8475437 Mrochen et al. Jul 2013 B2
8545487 Muller et al. Oct 2013 B2
8574277 Muller et al. Nov 2013 B2
8580789 Krueger et al. Nov 2013 B2
8652131 Muller et al. Feb 2014 B2
8712536 Muller et al. Apr 2014 B2
8784406 Rathjen Jul 2014 B2
8870934 Muller et al. Oct 2014 B2
8882757 Muller et al. Nov 2014 B2
8887734 Bueler et al. Nov 2014 B2
8936591 Mrochen et al. Jan 2015 B2
8945101 Herekar et al. Feb 2015 B2
8992023 Perez et al. Mar 2015 B2
8992516 Muller Mar 2015 B2
9006182 Soltz et al. Apr 2015 B2
9020580 Friedman et al. Apr 2015 B2
9044308 Muller et al. Jun 2015 B2
9125735 de Juan, Jr et al. Sep 2015 B2
9125856 Paik et al. Sep 2015 B1
9192594 Troisi et al. Nov 2015 B2
9289396 Devore et al. Mar 2016 B2
9411938 Rathjen Aug 2016 B2
9439908 Foschini et al. Sep 2016 B2
9445870 Chuck et al. Sep 2016 B2
9452172 Scherz et al. Sep 2016 B2
9463178 Smith Oct 2016 B2
9486284 Depfenhart et al. Nov 2016 B2
9498114 Friedman et al. Nov 2016 B2
9498122 Friedman et al. Nov 2016 B2
9498642 Muller et al. Nov 2016 B2
9504607 Russmann Nov 2016 B2
9555111 Rubinfeld et al. Jan 2017 B2
9566301 Rubinfeld et al. Feb 2017 B2
9622911 Rubinfeld et al. Apr 2017 B2
9664926 Mitsui May 2017 B2
9700456 Foschini et al. Jul 2017 B2
9707126 Friedman et al. Jul 2017 B2
9724233 Blumenkranz et al. Aug 2017 B2
9737438 Rathjen Aug 2017 B2
9788996 Roy et al. Oct 2017 B2
9802059 Saks Oct 2017 B2
9814567 Peyman Nov 2017 B2
9855168 Wellhoefer Jan 2018 B2
9861526 Cooper et al. Jan 2018 B1
9883970 Lopath et al. Feb 2018 B2
9889041 Iseli Feb 2018 B2
9907698 Cooper et al. Mar 2018 B2
9907977 Skerl Mar 2018 B2
10010449 Lopath Jul 2018 B2
10028657 Friedman Jul 2018 B2
10064753 Daxer Sep 2018 B2
10092594 Rubinfeld et al. Oct 2018 B2
10098782 Depfenhart Oct 2018 B2
10105350 Paik et al. Oct 2018 B2
10130511 Dantus Nov 2018 B2
10137239 Friedman et al. Nov 2018 B2
10141075 Dupps, Jr. Nov 2018 B2
10166314 Phopase et al. Jan 2019 B2
10182941 Hafezi et al. Jan 2019 B2
10195081 Peyman Feb 2019 B1
10219944 Tedford et al. Mar 2019 B2
10231968 Hardten et al. Mar 2019 B2
10258506 Depfenhart Apr 2019 B2
10258809 Friedman et al. Apr 2019 B2
10285857 Rubinfeld et al. May 2019 B2
10335316 Bor et al. Jul 2019 B2
10342697 Friedman et al. Jul 2019 B2
10345590 Samec et al. Jul 2019 B2
10350111 Friedman et al. Jul 2019 B2
10363170 Skerl et al. Jul 2019 B2
10383721 Marcos Celestino et al. Aug 2019 B2
10426659 Myung et al. Oct 2019 B2
10426663 Iseli Oct 2019 B2
10449090 Muller Oct 2019 B2
10463610 Williams et al. Nov 2019 B2
10463735 Xie et al. Nov 2019 B2
10569098 Depfenhart et al. Feb 2020 B2
10575986 Rubinfeld Mar 2020 B2
10729716 Rubinfeld et al. Aug 2020 B2
11033429 Rubinfeld et al. Jun 2021 B2
20010016731 DeVore et al. Aug 2001 A1
20010022063 Korteweg Sep 2001 A1
20020006394 Redmond et al. Jan 2002 A1
20020013577 Frey et al. Jan 2002 A1
20020022606 Kochevar et al. Feb 2002 A1
20020040218 Fujieda Apr 2002 A1
20020100990 Platt Aug 2002 A1
20020118338 Kohayakawa Aug 2002 A1
20030083649 Margaron et al. May 2003 A1
20030105521 Perez Jun 2003 A1
20030175259 Karageozian et al. Sep 2003 A1
20030203839 Kruzel et al. Oct 2003 A1
20030208190 Roberts et al. Nov 2003 A1
20030225041 Nolan Dec 2003 A1
20030232287 Bango Dec 2003 A1
20040137068 Bhushan Jul 2004 A1
20050070942 Perez Mar 2005 A1
20050090877 Harth et al. Apr 2005 A1
20050124982 Perez Jun 2005 A1
20050149006 Peyman Jul 2005 A1
20050152993 De Oliveira Jul 2005 A1
20050241653 Van Heugten et al. Nov 2005 A1
20050271590 Schwartz et al. Dec 2005 A1
20050283234 Zhou et al. Dec 2005 A1
20060073172 Schneider et al. Apr 2006 A1
20060074487 Gilg Apr 2006 A1
20060084951 Heacock et al. Apr 2006 A1
20060106371 Muhlhoff et al. May 2006 A1
20060134170 Griffith et al. Jun 2006 A1
20060166879 Bhushan et al. Jul 2006 A1
20060172972 Bhushan et al. Aug 2006 A1
20060177430 Bhushan et al. Aug 2006 A1
20060206173 Gertner et al. Sep 2006 A1
20060235513 Price Oct 2006 A1
20060254602 Myer Nov 2006 A1
20060268231 Gil et al. Nov 2006 A1
20060275278 Choy et al. Dec 2006 A1
20060287662 Berry et al. Dec 2006 A1
20070021806 Mercier et al. Jan 2007 A1
20070088415 Peyman Apr 2007 A1
20070128174 Kleinsek et al. Jun 2007 A1
20070129286 Zhang Jun 2007 A1
20070135805 Peyman Jun 2007 A1
20070142828 Peyman Jun 2007 A1
20070156077 Pfister Jul 2007 A1
20070167935 Serdarevic Jul 2007 A1
20070203478 Herekar Aug 2007 A1
20070207116 Brown Sep 2007 A1
20070225778 Heacock et al. Sep 2007 A1
20080009901 Redmond et al. Jan 2008 A1
20080015660 Herekar Jan 2008 A1
20080039769 Peyman Feb 2008 A1
20080057023 Chynn et al. Mar 2008 A1
20080089923 Burkstrand et al. Apr 2008 A1
20080097174 Maynard et al. Apr 2008 A1
20080114283 Mattson et al. May 2008 A1
20080139671 Herekar Jun 2008 A1
20080161780 Serdarevic Jul 2008 A1
20080208177 Mrochen et al. Aug 2008 A1
20080246920 Buczek et al. Oct 2008 A1
20080269119 Griffith et al. Oct 2008 A1
20080269730 Dotson Oct 2008 A1
20080288063 Price, Jr. Nov 2008 A1
20090024117 Muller Jan 2009 A1
20090069798 Muller et al. Mar 2009 A1
20090099557 Sedarevic Apr 2009 A1
20090105127 Thompson et al. Apr 2009 A1
20090149842 Muller et al. Jun 2009 A1
20090149923 Herekar Jun 2009 A1
20090171305 El Hage Jul 2009 A1
20090187178 Muller et al. Jul 2009 A1
20090187184 Muller Jul 2009 A1
20090192437 Soltz et al. Jul 2009 A1
20090209954 Muller et al. Aug 2009 A1
20090275923 Shimizu et al. Nov 2009 A1
20090275929 Zickler Nov 2009 A1
20100057059 Makino Mar 2010 A1
20100057060 Herekar Mar 2010 A1
20100069894 Mrochen et al. Mar 2010 A1
20100082018 Panthakey et al. Apr 2010 A1
20100087920 Marmo Apr 2010 A1
20100094197 Marshall et al. Apr 2010 A1
20100094280 Muller Apr 2010 A1
20100114109 Peyman May 2010 A1
20100173019 Paik et al. Jul 2010 A1
20100179622 Wagenaar Cacciola et al. Jul 2010 A1
20100185192 Muller et al. Jul 2010 A1
20100189817 Krueger et al. Jul 2010 A1
20100210996 Peyman Aug 2010 A1
20100256705 Muller et al. Oct 2010 A1
20100286156 Pinelli Nov 2010 A1
20100312198 Guidi Dec 2010 A1
20100318017 Lewis et al. Dec 2010 A1
20110060129 Akashi et al. Mar 2011 A1
20110060267 DeWoolfson et al. Mar 2011 A1
20110081323 Kleinsek et al. Apr 2011 A1
20110086802 Dewoolfson et al. Apr 2011 A1
20110098790 Daxer Apr 2011 A1
20110118654 Muller et al. May 2011 A1
20110125187 Soltz et al. May 2011 A1
20110149247 Artsyukhovich Jun 2011 A1
20110152219 Stagni Jun 2011 A1
20110160710 Frey et al. Jun 2011 A1
20110190742 Anisimov Aug 2011 A1
20110237999 Muller et al. Sep 2011 A1
20110264082 Mrochen et al. Oct 2011 A1
20110280763 Trokel et al. Nov 2011 A1
20110282333 Herekar et al. Nov 2011 A1
20110288466 Muller et al. Nov 2011 A1
20110301524 Bueler et al. Dec 2011 A1
20110306956 Islam Dec 2011 A1
20120059439 Yoon Mar 2012 A1
20120065572 Lewis et al. Mar 2012 A1
20120083772 Rubinfeld et al. Apr 2012 A1
20120087970 Newman Apr 2012 A1
20120095455 Rodmond et al. Apr 2012 A1
20120121567 Troisi et al. May 2012 A1
20120148543 Connon Jun 2012 A1
20120150160 Vogler et al. Jun 2012 A1
20120203161 Herekar Aug 2012 A1
20120215155 Muller et al. Aug 2012 A1
20120238938 Herekar et al. Sep 2012 A1
20120283531 Maynard et al. Nov 2012 A1
20120283621 Muller Nov 2012 A1
20120289886 Muller et al. Nov 2012 A1
20120303008 Muller et al. Nov 2012 A1
20120310083 Friedman et al. Dec 2012 A1
20120310141 Kornfield et al. Dec 2012 A1
20130060187 Friedman et al. Mar 2013 A1
20130079759 Dotson et al. Mar 2013 A1
20130085370 Friedman et al. Apr 2013 A1
20130110091 Berry May 2013 A1
20130131664 Muller et al. May 2013 A1
20130158342 Chan et al. Jun 2013 A1
20130245536 Friedman et al. Sep 2013 A1
20130267528 Pinelli Oct 2013 A1
20130331768 Nichamin Dec 2013 A1
20140024997 Muller et al. Jan 2014 A1
20140031845 Rynerson Jan 2014 A1
20140142200 Duan et al. May 2014 A1
20140155800 de Juan, Jr et al. Jun 2014 A1
20140171490 Gross et al. Jun 2014 A1
20140276361 Herekar et al. Sep 2014 A1
20140320819 Muller et al. Oct 2014 A1
20140343480 Kamaev et al. Nov 2014 A1
20140368792 Friedman et al. Dec 2014 A1
20140368793 Friedman et al. Dec 2014 A1
20150032686 Kuchoor Jan 2015 A1
20150088231 Rubinfeld et al. Mar 2015 A1
20150126921 Rubinfeld et al. May 2015 A1
20150174161 Rubinfeld et al. Jun 2015 A1
20150182659 Fabian Jul 2015 A1
20150305933 Zhou Oct 2015 A1
20150359668 Kornfield et al. Dec 2015 A1
20160038760 Hamrah et al. Feb 2016 A1
20160151202 Scarcelli et al. Jun 2016 A1
20160175442 Kamaev et al. Jun 2016 A1
20160236006 Donitzky et al. Aug 2016 A1
20160303284 Borde et al. Oct 2016 A1
20160325499 Muller Nov 2016 A1
20170021021 Kamaev et al. Jan 2017 A1
20170043015 Alageel et al. Feb 2017 A1
20170156926 Friedman et al. Jun 2017 A1
20170246471 Lopath Aug 2017 A1
20170367879 Lopath et al. Dec 2017 A1
20180028834 Saks Feb 2018 A1
20180050088 Green et al. Feb 2018 A1
20180078677 Cho et al. Mar 2018 A1
20180098884 Ko et al. Apr 2018 A1
20180177587 Anderson et al. Jun 2018 A1
20180193188 Vukelic et al. Jul 2018 A1
20180206719 Adler et al. Jul 2018 A1
20180214552 Sui et al. Aug 2018 A1
20180228599 Elisseeff et al. Aug 2018 A1
20180236261 Smith et al. Aug 2018 A1
20180243082 Zheleznyak et al. Aug 2018 A1
20180353629 Neister et al. Dec 2018 A9
20190008683 Mitsui Jan 2019 A1
20190022220 Goldberg et al. Jan 2019 A1
20190083529 Ambati et al. Mar 2019 A1
20190159934 Bischoff et al. May 2019 A1
20190192840 Friedman et al. Jun 2019 A1
20190201710 Shiuey Jul 2019 A1
20190255226 Jessop et al. Aug 2019 A1
20190314548 Shiuey Oct 2019 A1
Foreign Referenced Citations (84)
Number Date Country
2319087 Aug 1999 CA
2418306 Jan 2002 CA
2473703 Jul 2003 CA
2511217 Jul 2004 CA
2515720 Sep 2004 CA
2566961 Dec 2005 CA
2576308 Feb 2006 CA
2577025 Feb 2006 CA
2700884 Feb 2009 CA
10323422 Apr 2004 DE
102013004482 Sep 2014 DE
102014017197 Jun 2016 DE
102016006083 Nov 2017 DE
102017104024 Aug 2018 DE
330389 May 1997 EP
590772 Apr 1998 EP
1051655 Sep 2005 EP
1561440 Apr 2009 EP
2077900 Jul 2009 EP
1790383 Jul 2010 EP
2253321 Nov 2010 EP
2323642 Feb 2014 EP
2407132 Apr 2014 EP
2236109 Oct 2014 EP
2802302 Nov 2014 EP
2663281 Aug 2016 EP
2797492 Dec 2017 EP
3288588 Aug 2018 EP
3122296 Oct 2018 EP
3407920 Dec 2018 EP
3426219 Jan 2019 EP
3458000 Mar 2019 EP
2712311 Jun 2019 EP
3053553 Sep 2019 EP
3003375 Nov 2019 EP
54101440 Aug 1979 JP
1803110 Mar 1993 RU
200063079 Oct 2000 WO
0111716 Feb 2001 WO
2001082933 Nov 2001 WO
03061518 Jul 2003 WO
03068247 Aug 2003 WO
2004024035 Mar 2004 WO
2005117987 Dec 2005 WO
2007011874 Jan 2007 WO
2007011875 Jan 2007 WO
2007020673 Feb 2007 WO
2007026382 Mar 2007 WO
2007035843 Mar 2007 WO
2007082127 Jul 2007 WO
2008005059 Jan 2008 WO
2008055118 May 2008 WO
2009146151 Dec 2009 WO
2010011119 Jan 2010 WO
2010019072 Feb 2010 WO
2009001396 Mar 2010 WO
2010023705 Mar 2010 WO
2010093908 Aug 2010 WO
2011011202 Jan 2011 WO
2011019940 Feb 2011 WO
2011041437 Apr 2011 WO
2011050164 Apr 2011 WO
2011050164 Apr 2011 WO
2011056477 May 2011 WO
2011109712 Sep 2011 WO
2011152861 Dec 2011 WO
2012035403 Mar 2012 WO
2012047307 Apr 2012 WO
2013148895 Oct 2013 WO
2013148896 Oct 2013 WO
2013158611 Oct 2013 WO
2014066636 May 2014 WO
2014071408 May 2014 WO
2014089548 Jun 2014 WO
2014145666 Sep 2014 WO
2014174544 Oct 2014 WO
2016178586 Nov 2016 WO
2016195152 Dec 2016 WO
2017184717 Oct 2017 WO
2018144477 Aug 2018 WO
2018156593 Aug 2018 WO
2019149802 Aug 2018 WO
2018213795 Nov 2018 WO
2019173759 Sep 2019 WO
Non-Patent Literature Citations (87)
Entry
Communication Pursuant to Article 94(3) EPC issued in EP13767439.6 dated Dec. 9, 2019.
Third Party Observation for European application No. 13767439.6 submitted to the European Patent Office on Apr. 13, 2019 in 2 pages.
Baranowski, “Ophthlamic Drug Dosage Forms: Characterisation and Research Methods,” The Scientific World Journal, vol. 2014, pp. 1-14 (2014).
Kim et al. (Wiley Periodicals, Wiley InterScience, Jun. 2009, pp. 390-400, 2009.
Xie et al., Progress in Polymer Science, 2019, vol. 95, pp. 32-64, 2019.
Arbelaex et al., Oman Journal of Ophthamalogy, 2009, vol. 2, pp. 33-38, 2009.
Baldursdottir et al. (Biomacromolecules, 2003, vol. 4, pp. 429-436) (Year: 2003).
El-Raggal (Riboflavin-Ultraviolet A Corneal Cross linking for Keratoconus, Middle East Afr. J. Ophthalmol. Oct.-Dec. 2009; 16(4):256-259).
Bessonova, et al., “A study of the stability of eye drops containing riboflavine (Russian).” XP002719481. Database accession No. EMB-1978057912. Abstract Elseview Science Publishers, Amsterdam, NL 1977.
Elstner, et al. “Uptake and biochemical activity of potassium iodide in isolated rabbit eyes.” XP008167001. Phtlalmologica 191(2):122-126 (1985). English Abstract.
Koltun, et al. “improving the production technology of vitamin-containing eye drops to ensure their microbiological purity.” CP00271948, Database accession No. PREV199497454025. Abstract Biosciences information service, Philadelphia, PA, 1993.
Rieger, “Anti-oxidtaive capacity of various articifial tear prepartions.” XPO003014992, Graefe's Archive for Clinical Experimental Ophthalmology. 239:222-226 (2001).
Schmut, et al. “Iodide protection from UVB irradiation-induced degradation of hyaluronate and against UVB- damaage of human conjunctival fibroblasts.” Graefe's Arch Clin Exp Ophthalmol 242:279-283 2004.
Shimmura, et al. “Subthershold UV radiation-induced peroxide formation in cultured coreal epithelial cells: the protective effects of lactoferrin” Exp. Eye Res. 63: 519-526 1996.
Ishimitsu “The photochemical decomposition and hydroxylation of phenylalanine in the presence of riboflavin” Chem. Pharm. Bul. 33(4): 1552-1556 1985.
Zhang, et al. “Clinical effect of traditional Chinese herb combined with sodium iodide in treating corneal opacity.” XP-002719483, International Journal of Ophthalmology, 7: 217-219, 2007.
Extended European Search Report dated Feb. 10, 2014 for related EP Patent Application No. 11831060 in 15 pages.
Cho et al. “Reactive Oxygen Species-Induced Apoptosis and Necrosis in Bovine Corneal Endothelial Cells.” Investigative Ophthalmology & Visual Science. 40(5):911-919, Apr. 1999.
Fujimori. “Cross-linking and fluorescence changes of collagen by glycation and oxidation.” Biochimica et Biophysica Acta. 998:105-110, 1989.
Hull et al. “Hydrogen Peroxide-Mediated Corneal Endothelial Damage.” Investigative Ophthalmology & Visual Science. 25:1246-1253, 1984.
Iseli et al. “Efficacy and Safety of Blue-light Scleral Cross-linking.” International Congress of Corneal Cross-Linking, Dec. 7-8, 2007; Zurich, Switzerland. pp. S752-S755.
Khadem et al. “Photodynamic Biologic Tissue Glue.” Cornea. 13(5):406-410, 1994.
Kohlhaas et al. “Biomechanical evidence of the distribution of cross-links in corneas treated with riboflavin and ultraviolet A light.” J Cataract Refract Surg. 32:279-283, Feb. 2006.
Krueger et al. “Rapid vs Standard Collagen CXL with Equivalent Energy Dosing.” Third International Congress of Corneal Cross-linking. Dec. 7-8, 2007; Zurich, Switzerland, in 25 pages.
Sato et al. “The Primary Cytotoxicity in Ultraviolet-A-Irradiated Riboflavin Solution is Derived from Hydrogen Peroxide.” The Society for Investigative Dermatology, Inc. 105(4):608-612, Oct. 1995.
Seiler et al. “Corneal Cross-Linking-Induced Stromal Demarcation Line.” Clinical Science. 25(9):1057-1059, Oct. 2006.
Spoerl et al. “Increased resistance of cross-linked cornea against enzymatic digestion.” Current Eye Research. 29(1):35-40, 2004.
Spoerl et al. “Induction of Cross-links in Corneal Tissue.” Exp. Eye Res. 66:97-103, 1998.
Spoerl et al. “Safety of UVA-Riboflavin Cross-Linking of the Cornea.” Cornea. 26(4):385-389, May 2007.
Spoerl et al. “Thermo-mechanical Behavior of Collagen-Cross-Linked Porcine Cornea.” Ophthalmologica. 218:136-140, 2004.
Wollensak et al. “Collagen Fiber Diameter in the Rabbit Cornea After Collagen Cross-linking by Riboflavin/UVA.” Cornea. 23(5):503-507, Jul. 2004.
Wollensak et al. “Corneal Endothelial Cytotoxicity of Riboflavin/UVA Treatment in vitro.” Ophthalmic Res. 35:324-328, 2003.
Wollensak et al. “Endothelial cell damage after riboflavin-ultraviolet-A treatment in the rabbit.” J Cataract Refract Surg. 29:1786-1790, 2003.
Wollensak et al. “Keratocyte Apoptosis After Corneal Collagen Cross-linking Using Riboflavin/UVA Treatment.” Cornea. 23(1):43-49, Jan. 2004.
Wollensak et al. “Keratocyte cytotoxicity of riboflavin/UVA treatment in vitro.” Eye. 2004, in 5 pages.
Wollensak et al. “Long-term biomechanical properties of rabbis cornea after photo-dynamic collagen cross-linking.” Acta Ophthalmologica. 87:48-51, 2009.
Wollensak et al. “Riboflavin/Ultraviolet-A-induced Collagen Cross-linking for the Treatment of Keratoconus.” Am J Ophthalmol. 135:620-627, 2003.
Wollensak et al. “Stress-strain measurements of human and porcine corneas after riboflavin-ultraviolet-A-induced cross-linking.” J Cataract Refract Surg. 29:1780-1785, 2003.
Wollensak et al. “Wound Healing in the Rabbit Cornea After Corneal Collagen Cross-Linking With Riboflavin and UVA.” Cornea. 26:600-605, 2007.
International Search Report and Written Opinion for related international application No. PCTUS2013/034185, dated Jul. 11, 2013, in 10 pages.
International Search Report and Written Opinion for related international application No. PCTUS2013033923, dated Jul. 12, 2013, in 11 pages.
Epstein.“Refraktive Chirurgie.” Therapeutische Umschau. Revue Therapeutique. 66(3):207-210 (Mar. 2009). English abstract.
Chuo et al. “Modern Corneal and Refractive Procedures.” Expert Review of Ophthalmology. 6(2):247-266 (Apr. 2011).
Kullman. “Alternative Applications of the Femtosecond Laser in Ophthalmology.” Seminars in Ophthalmology. 25(5-6):256-264 (Nov. 2010).
Kohnen et al. “Bewertung und Qualitätssicherung refraktiv-chirurgischer Eingriffe durch die DOG und den BVA (Evaluation and quality assurance of refractive surgery by the German Ophthalmological Society and the Professional Association of German Ophthalmologists).” Ophthalmologie. 108(9):869-882 (Sep. 2011). Available only in German.
Kato et al. “Topography-Guided Conductive Keratoplasty: Treatment for Advanced Keratoconus.” American Journal of Ophthalmology. 150(4):481-489 (Oct. 2010).
Oduntan et al. “A review of the role of oxidative stress in the pathogenesis of eye diseases.” S Afr Optom. 70(4):191-199 (2011).
Gilgun-Sherki et al. Oxidative stress induced neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier, Neuropharmacology 40: 959-975, 2001.
Bickers et al. “Oxidative Stress in the Pathogenesis of Skin Disease.” The Society for Investigative Dermatology. pp. 2565-2575, 2006.
Sukkar et al. “Oxidative stress and nutritional prevention in autoimmune rheumatic diseases.” Autoimmunity Reviews. 3:199-206 (2004).
Uttara et al. “Oxidative Stress and Neurodegenerative Diseases: A Review of Upstream and Downstream Antioxidant Therapeutic Options.” Current Neuropharmacology. 7:65-74 (2009).
Wells et al. “Oxidative Stress in Developmental Origins of Disease: Teratogenesis, Neurodevelopmental Deficits, and Cancer.” Toxicological Sciences. 108(1):4-18 (2009).
EMX Industries, Inc .; ColoMax HEX color sensors; Mar. 2010.
International Search Report and Written Opinion for related PCT/US2014/024770 dated Aug. 6, 2014 in 17 pages.
Wollensak et al., “Cross-linking of scleral collagen in the rabbit using riboflavin and UVA”, ACTA Ophthalmologica Scandinavica, 2005, vol. 83, pp. 477-482.
International Search Report and Written Opinion for related international application No. PCT/US2013/034467 dated Jul. 26, 2013 in 12 pages.
Agbor, et al. “Effect of Iodine Supplementation on Antioxidant Status of Normal and Alloxan Monohydrate in Toxicated Rats”, International Journal of Pharmacology, 7 (6): pp. 726-731, 2011, Asian Network for Scientific Information.
Rieger, et al. “The Effect of lodide lontophoresis on the Antioxidative Capacity of the Tear Fluid” Graefe's Archive for Clinical Experimental Ophthalmology. 248:1639-1646 (2010).
Supplementary European Search Report for EP 13767439.6 dated Sep. 15, 2015 in 6 pages.
Horwath-Winter J, et al: “Iodide iontophoresis as a treatment for dry eye syndrome”, The British Journal of Ophthalmology, Jan. 2005, pp. 40-44, vol. 89, No. 1.
Singh et al: “Clinical Evaluation of Sodium Iodide in the Treatment of Various Types of Cataracts”, Journal of the Indian Medical Association, 1983, pp. 119-121, vol. 81, No. 7-8.
Winkler et al: “Effect of Iodide on Total Antioxidant Status of Human Serum”, Cell Biochemistry and Function, Jun. 2000, pp. 143-146, vol. 18, No. 2.
Partial supplementary European Search Report for EP 13768403.1 dated Oct. 23, 2015 in 10 pages.
Ilens Ophthalmic Solution, http://naikutty.in/medicine-list-i/article/86937-ilens-solution, Date unknown but available prior to the date of this application, access date Dec. 22, 2015.
J. Wernli, S. Schumacher, E. Spoerl, and M. Mrochen, “The efficacy of corneal cross-linking shows a sudden decrease with very high intensity UV light and short treatment time,” Investigative Ophthalmology and Visual Science, vol. 54, No. 2, pp. 1176-1180, Feb. 2013.
R. R. Krueger, E Spoerl, and S. Herekar, “Rapid vs standard collagen CXL with equivalent energy dosing,” in Proceedings of the 3rd International Congress of Corneal Collagen Cross-Linking, Zurich, Switzerland, Dec. 2007.
Pavel Kamaev, et al,. “Photochemical kinetics of corneal cross-linking with Riboflucin”, Investigative Ophthalmology and Visual Science, Apr. 2012, vol. 53, No. 4, 2360-2367.
Extended European Search Report dated Oct. 19, 2016 for related EP Patent Application No. 14775693.6 in 8 pages.
International Search Report and written opinion dated Jan. 17, 2012 for PCT/US2011/033873.
Olson, “Control lamp flora in developed caves” Heldreth-Werker V. & Werker J.C. Cave Conservation and Restoration, Huntsville: National Speleolgical Society: 343-348.
Baert, et al “Medical Radiology: Diagnostic Imaging, Radiological Imaging of the Ureter, copyright 2003, Springer” (Joffre, et all.) DOI https://doi.org/10.1007/978-3-642-55831-3.
Abraxis (Iodopen MSDS, Revision date of Jun. 13, 2006).
International Preliminary Report on patentability for PCT/US2013/034185, dated Oct. 1, 2014, in 7 pages.
Harvey, et al. “Formulation and stability of a novel artificial human sweat under conditions of storage and use” Toxicology in Vitro, 2010, vol. 24, pp. 1790-1796.
International Preliminary Report on patentability for PCT/US2013/034467, dated Oct. 1, 2014, in 6 pages.
Extended European Search Report issued in EP18196714.2 dated Jan. 30, 2019 in 8 pages.
Rose, R. C. et al.: “Ocular oxidants and antioxidant protection”, Experimental Biology and Medicine, vol. 217, No. 4, 1998, pp. 397-407.
Ibusuki et al.: “Photochemically Cross-Linked Collagen Gels as Three-Dimensional Scaffolds for Tissue Engineering”, Tissue Engineering, vol. 13, No. 8, Aug. 14, 2007, pp. 1995-2001.
Third Party Observation for European application No. 13767439.6 submitted to the European Patent Office on Nov. 30, 2018, in 2 pages.
Hafezi, Cross-linking of corneal collagen with UVA and riboflavin for the treatment of corneal disease,2009, Iranian Journal of Ophthalmology, col. 21, No. 2, pp. 3-12/.
Letko, et al. UVA-light and riboflavin-mediated corneal collagen cross-linking, 2011 International ophthalmology climics. Www.intrnat-ophthalmology.com, pp. 1-14.
Beijin Yasi Technology and Development Co., Ltd Eye sponge product information, Jul. 29, 2011.
International Search Report and Written Opinion issued in PCT/US2013/034187 dated Jul. 22, 2013 in 21 pages.
Extended European Search Report for European application No. 18182071.3 dated Oct. 2, 2018 in 6 pages.
Extended European Search Report for European application No. 15793441.5 dated Jan. 2, 2017.
International Search Report and Written Opinion for PCT/US2015/029011 dated Aug. 3, 2015 in 14 pages.
Iseli et al., Laboratory Measurement of the Absorption Coefficient of Riboflavin for Ultraviolet Light (365 nm), Journal of Refractive Surgery, 2011, 27(3):195-201, Jun. 4, 2010, 3 pages.
Related Publications (1)
Number Date Country
20200146886 A1 May 2020 US
Provisional Applications (1)
Number Date Country
61617339 Mar 2012 US
Continuations (1)
Number Date Country
Parent 14275192 May 2014 US
Child 16738735 US
Continuation in Parts (1)
Number Date Country
Parent PCT/US2013/034187 Mar 2013 US
Child 14275192 US